论文部分内容阅读
原发于肺支气管的神经内分泌肿瘤(BPNETs)占原发性肺肿瘤的25%,在WHO(2004)分类中分为四种亚型,各亚型有着相应的形态学特点和诊断标准。SCLC(小细胞肺癌)最为常见,约占20%;其次为LCNEC(大细胞神经内分泌癌),约占3%;TC(典型类癌)约2%;AC(不典型类癌)约0.2%。2011年肺腺癌的国际多学科新分类方案列出的BPNETs分类引发了进一步关注。本研究将重点关注BPNETs的病理学诊断和分子遗传学方面的进展,并结合该病各类型的预后进行探讨。
Neuroendocrine tumors (BPNETs) in primary bronchial lungs account for 25% of primary lung tumors and are classified into four subtypes in the WHO (2004) classification with corresponding morphological features and diagnostic criteria. SCLC (small cell lung cancer) is the most common, accounting for about 20%; followed by LCNEC (large cell neuroendocrine carcinoma), accounting for about 3%; TC (typical carcinoid) about 2%; AC (atypical carcinoid) about 0.2% . The BPNETs classification of the 2011 International Multidisciplinary New Classification of Lung Adenocarcinoma raises further concerns. This study will focus on the pathological diagnosis of BPNETs and molecular genetics advances, combined with the prognosis of various types of disease to explore.